Live Vaccines to Avoid with Cosentyx
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses the immune system. Avoid live vaccines at least 4 weeks before starting treatment and during therapy, as they can cause uncontrolled infection.[1][2]
Examples include:
- MMR (measles, mumps, rubella)
- Varicella (chickenpox)
- Oral polio
- Yellow fever
- Live shingles (Zostavax; note: recombinant Shingrix is safe)
- Live typhoid and rotavirus vaccines
Why Live Vaccines Pose Risks
Live vaccines contain weakened but replicating virus or bacteria, which can multiply in immunocompromised patients on Cosentyx, leading to serious infections like disseminated varicella or measles.[2][3] The drug's label warns of this interaction, recommending completion of live vaccines pre-treatment.
Safe Alternatives Before Starting Cosentyx
Inactivated or recombinant vaccines are generally okay:
- Inactivated flu shot
- Tdap (tetanus, diphtheria, pertussis)
- Pneumococcal (PCV13 or PPSV23)
- HPV
- Recombinant shingles (Shingrix)
- COVID-19 vaccines (mRNA or protein-based)
Consult your doctor for timing; some may need boosters before or after starting.[1][4]
Timing and Special Cases
Finish live vaccines 4+ weeks before Cosentyx. If already on treatment, delay non-urgent live vaccines until after stopping (wait 4-6 months post-last dose).[2] For travel or outbreaks, discuss risk-benefit with your provider—exceptions are rare. Kids or household contacts can get live vaccines, but avoid close contact for 4 weeks post-vaccination.[3]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: CDC Guidelines on Immunization and Immunosuppressants
[4]: ACR Guidelines for Vaccinations in Rheumatic Diseases